**Three Ultra-High-Yield Dividend Stocks to Consider for June Investments**

Investors seeking stable income and long-term growth have always had a reliable ally in dividend stocks. Historically, these stocks have outperformed their non-dividend-paying counterparts, offering both robust returns and reduced volatility. Currently, three standout dividend stocks, yielding an impressive average of 11.35%, have emerged as compelling options for June.

**Annaly Capital Management: Leading the Charge**

The first on the list is Annaly Capital Management, a prominent mortgage real estate investment trust (REIT). Despite Wall Street's general aversion to mortgage REITs due to their sensitivity to interest rate changes, Annaly presents a strong case for investment. Recently, Annaly increased its quarterly distribution to $0.70 per share, marking the first increase since 2011. The company's nearly 15% yield, though seemingly high, is backed by a 20-year average yield of approximately 10%.

While rising interest rates have posed challenges for mortgage REITs, current economic conditions suggest a shift in favorability. The easing Federal Reserve rates and a stabilized Treasury yield curve enhance Annaly’s prospects. Their $84.9 billion asset portfolio, predominantly composed of highly liquid agency securities, offers added security. Trading slightly below its book value, Annaly Capital Management is positioned as a robust income-generating option.

**Pfizer: A Strong Contender in Pharmaceuticals**

Next is pharmaceutical giant Pfizer, with a notable dividend yield of over 7.3%. Despite a notable decline in sales from its COVID-19 therapies, Pfizer remains strong. The company’s acquisition of Seagen in December 2023 for $43 billion significantly strengthened its oncology pipeline, promising sustained revenue and growth.

Pfizer’s defensive position in the healthcare sector ensures stable demand for its products regardless of broader market conditions. The company’s ongoing cost realignment initiatives and acquisition synergies are expected to contribute to substantial cost savings, boosting margins. Considering Pfizer's strong financials and low trading multiple of less than 8 times forecasted earnings for 2025, this stock offers a promising opportunity for income-focused investors.

**PennantPark Floating Rate Capital: Elevated Monthly Dividends**

Lastly, PennantPark Floating Rate Capital stands out with a yield close to 12%. This business development company (BDC) focuses on providing debt to middle-market companies, boasting a weighted average yield on debt investments of 10.5% as of March 31. The company’s predominantly variable-rate debt investments have benefited from the recent interest rate hikes.

Despite dealing with smaller, unproven companies, PennantPark has maintained minimal delinquencies, indicative of rigorous vetting processes. Moreover, their diversified portfolio, with an average investment of $14.7 million across 159 companies, ensures stability. Trading at a 7% discount to its book value, PennantPark Floating Rate Capital offers a lucrative option for investors seeking regular monthly dividends.

In summary, Annaly Capital Management, Pfizer, and PennantPark Floating Rate Capital present compelling cases as high-yield dividend stocks for June. Each combines strong financial fundamentals, strategic positioning, and impressive yields, making them attractive options for income-seeking investors.